Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Application
Filed:
December 24, 2012
Publication date:
August 22, 2013
Applicants:
PURDUE PHARMA L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Grant
Filed:
October 30, 2008
Date of Patent:
March 5, 2013
Assignees:
Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals, L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises forming spheroids comprising a spheronising agent and oxycodone or a salt thereof, and coating the spheroids with a controlled-release film coat. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration.
Type:
Application
Filed:
September 5, 2012
Publication date:
January 10, 2013
Applicants:
Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.
Inventors:
Benjamin Oshlack, John Joseph Minogue, Mark Chasin, Robert Francis Kaiko
Abstract: A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises wet granulating at least one hydrophilic or hydrophobic polymer, preferably a hydroxyalkyl cellulose or an alkyl cellulose, with oxycodone or a salt thereof to form a controlled-release matrix. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration.
Type:
Application
Filed:
September 5, 2012
Publication date:
January 10, 2013
Applicants:
Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.
Inventors:
Benjamin Oshlack, John Joseph Minogue, Mark Chasin, Robert Francis Kaiko
Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
Type:
Application
Filed:
February 6, 2012
Publication date:
January 3, 2013
Applicants:
Purdue Pharma L.P., Rhodes Technologies, Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.
Inventors:
Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper